The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

3 months ago

Version History

Version 13 months ago

What changed: Added details regarding the drug's medical application (CRS prevention), the timeline for interim results (Summer 2024), and the company's secondary market listings.

StocksMediumUpdated•Originally published 16 April 2026•Updated 16 April 2026•

1 min read

Poolbeg Pharma Shares Surge on UK MHRA Clearance for POLB 001 Study

Key Facts

1Poolbeg Pharma received Clinical Trial Authorisation from the UK MHRA for its POLB 001 TOPICAL study.

2Cavendish labeled the milestone a key de-risking event, projecting a 313% upside to the target price.

3Shares of the company rose as much as 8% following the announcement of the regulatory clearance.

Poolbeg Pharma, listed on the AIM market (POLB), has secured Clinical Trial Authorisation from the UK MHRA for its POLB 001 study. The drug is being developed as a preventative therapy for cytokine release syndrome (CRS) triggered by cancer immunotherapies, a move Cavendish describes as a significant de-risking event. Shares surged 8% following the news, with analysts maintaining a target price implying a 313% upside. Investors are now looking toward the summer of 2024, when interim data from the clinical trial is expected to be released. In addition to its London listing, the company trades on the OTC and Frankfurt markets under the ticker POLBF. This regulatory clearance represents the final hurdle before commencing patient screening and strengthens Poolbeg's position in the biotech sector.

Sources:

proactiveinvestors.co.uk